References
- Visser O, Trama A, Maynadie M, et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012;48:3257-66
- Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006;24:5358-65
- Meers S, Breems D, Bries G, et al. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society. Acta Clin Belg 2013;68:253-62
- Ria R, Moschetta M, Reale A, et al. Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 2009;4:413-23
- Greenberg PL, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88
- Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011;9:30-56
- Khan C, Pathe N, Fazal S, et al. Azacitidine in the management of patients with myelodysplastic syndromes. Ther Adv Hematol 2012;3:355-73
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32
- The U.S. Food and Drug Administration Administration. FDA Approves New Drug for Bone Marrow Disease. 2004. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108300.htm. Accessed on May 12, 2014
- Agency EM. European Public Assessment Report (EPAR). Vidaza. EPAR summary for the public. 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000978/WC500050240.pdf. Accessed on May 12, 2014
- Muller A, Florek M. 5-Azacytidine/azacitidine. Recent Results Cancer Res 2010;184:159-70
- Field T, Perkins J, Huang Y, et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010;45:255-60
- Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med 2010;77:37-44
- Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40
- Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95
- van der Helm LH, Alhan C, Wijermans PW, et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol 2011;155:599-606
- Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013;98:1067-72